Treatment of a B-ALL/BM-MSC coculture system with an irreversible glutamine synthase inhibitor, methionine-L-sulfoxamine (MSO), in combination with ASNase significantly reduced the viability of B-ALL cells when compared with ASNase treatment alone. The gene discussed is GLUL; the disease is acute lymphoblastic leukemia.